1
|
Wang JQ, Liang J, Wang JL, Shan F, Cao Y, Zhou X, Yan CY, Xia QR, Liu YR. Evaluation of plasma-derived extracellular vesicles miRNAs and their connection with hippocampal mRNAs in alcohol use disorder. Life Sci 2024; 351:122820. [PMID: 38857652 DOI: 10.1016/j.lfs.2024.122820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 06/05/2024] [Accepted: 06/07/2024] [Indexed: 06/12/2024]
Abstract
Alcohol use disorder (AUD) is a common mental illness with high morbidity and disability. The discovery of laboratory biomarkers has progressed slowly, resulting in suboptimal diagnosis and treatment of AUD. This study aimed to identify promising biomarkers, as well as the potential miRNA-mRNA networks associated with AUD pathogenesis. RNA sequencing was performed on plasma-derived small extracellular vesicles (sEVs) from AUD patients and healthy controls (HCs) to harvest miRNAs expression profiles. Machine learning (ML) models were built to screen characteristic miRNAs, whose target mRNAs were analyzed using TargetScan, miRanda and miRDB databases. Gene Expression Omnibus (GEO) datasets (GSE181804 and GSE180722) providing postmortem hippocampal gene expression profiles of AUD subjects were mined. A total of 247 differentially expressed (DE) plasma-derived sEVs miRNAs and 122 DE hippocampal mRNAs were obtained. Then, 22 overlapping sEVs miRNAs with high importance scores were gained by intersecting 5 ML models. As a result, we established a putative sEVs miRNA-hippocampal mRNA network that can effectively distinguish AUD patients from HCs. In conclusion, we proposed 5 AUD-representative sEVs miRNAs (hsa-miR-144-5p, hsa-miR-182-5p, hsa-miR-142-5p, hsa-miR-7-5p, and hsa-miR-15b-5p) that may participate in the pathogenesis of AUD by modulating downstream target hippocampal genes. These findings may provide novel insights into the diagnosis and treatment of AUD.
Collapse
Affiliation(s)
- Jie-Quan Wang
- Department of Pharmacy, Affiliated Psychological Hospital of Anhui Medical University, Hefei 230000, China; Psychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei 230000, China; Department of Pharmacy, Hefei Fourth People's Hospital, Hefei 230000, China; Anhui Clinical Research Center for Mental Disorders, Hefei 230000, China
| | - Jun Liang
- Department of Pharmacy, Affiliated Psychological Hospital of Anhui Medical University, Hefei 230000, China; Psychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei 230000, China; Department of Pharmacy, Hefei Fourth People's Hospital, Hefei 230000, China; Anhui Clinical Research Center for Mental Disorders, Hefei 230000, China
| | - Jin-Liang Wang
- Department of Pharmacy, Affiliated Psychological Hospital of Anhui Medical University, Hefei 230000, China; Psychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei 230000, China; Department of Pharmacy, Hefei Fourth People's Hospital, Hefei 230000, China; Anhui Clinical Research Center for Mental Disorders, Hefei 230000, China
| | - Feng Shan
- Department of Pharmacy, Affiliated Psychological Hospital of Anhui Medical University, Hefei 230000, China; Psychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei 230000, China; Department of Pharmacy, Hefei Fourth People's Hospital, Hefei 230000, China; Anhui Clinical Research Center for Mental Disorders, Hefei 230000, China
| | - Yin Cao
- Department of Pharmacy, Affiliated Psychological Hospital of Anhui Medical University, Hefei 230000, China; Psychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei 230000, China; Department of Pharmacy, Hefei Fourth People's Hospital, Hefei 230000, China; Anhui Clinical Research Center for Mental Disorders, Hefei 230000, China
| | - Xuan Zhou
- Department of Pharmacy, Affiliated Psychological Hospital of Anhui Medical University, Hefei 230000, China; Psychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei 230000, China; Department of Pharmacy, Hefei Fourth People's Hospital, Hefei 230000, China; Anhui Clinical Research Center for Mental Disorders, Hefei 230000, China
| | - Chun-Yu Yan
- Department of Pharmacy, Affiliated Psychological Hospital of Anhui Medical University, Hefei 230000, China; Psychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei 230000, China; Department of Pharmacy, Hefei Fourth People's Hospital, Hefei 230000, China; Anhui Clinical Research Center for Mental Disorders, Hefei 230000, China
| | - Qing-Rong Xia
- Department of Pharmacy, Affiliated Psychological Hospital of Anhui Medical University, Hefei 230000, China; Psychopharmacology Research Laboratory, Anhui Mental Health Center, Hefei 230000, China; Department of Pharmacy, Hefei Fourth People's Hospital, Hefei 230000, China; Anhui Clinical Research Center for Mental Disorders, Hefei 230000, China.
| | - Ya-Ru Liu
- Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei 230001, China; The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei 230001, China.
| |
Collapse
|
2
|
Geng J, Jinli S, Guo W, Li H, Dan Y, Gao Y. Expression and clinical significance of CA125, CA153 and CEA in nipple discharge of breast cancer patients. J Med Biochem 2024; 43:234-242. [PMID: 38699697 PMCID: PMC11062330 DOI: 10.5937/jomb0-45192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Accepted: 08/30/2023] [Indexed: 05/05/2024] Open
Abstract
Background It is an important clinical means to identify benign and malignant breast diseases caused by nipple discharge through the detection and analysis of components in nipple discharge. This study was aimed to test the expression and clinical significance of carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153) and carcinoembryonic antigen (CEA) in nipple discharge of breast cancer patients. Methods From January 2017 to December 2018, 86 patients with invasive ductal carcinoma of the breast with nipple discharge (breast cancer group) and 50 patients with ordinary breast duct hyperplasia with nipple discharge (benign control group) were selected, and the levels of CA125, CA153 and CEA in nipple discharge and serum were detected by electrochemiluminescence immunoassay.
Collapse
Affiliation(s)
- Jun Geng
- Jinan Central Hospital, Medical Laboratory Diagnosis Center, Jinan, China
| | - Shi Jinli
- Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Emergency Center, Qingdao, China
| | - Weina Guo
- Affiliated Qingdao Central Hospital of Qingdao University, Qingdao Cancer Hospital, Health Management Center, Qingdao, China
| | - Haiyan Li
- Zhangqiu District People's Hospital, Department of Anesthesiology, Jinan, China
| | - Yang Dan
- Zhangqiu District People's Hospital, Department of Otolaryngology, Jinan, China
| | - Yan Gao
- Dongguan Town Hospital, Medical Laboratory Diagnosis Center, Department of Clinical Laboratory, Dongguan, China
| |
Collapse
|
3
|
Vissers TACM, Piek L, Patuleia SIS, Duinmeijer AJ, Bakker MF, van der Wall E, van Diest PJ, van Gils CH, Moelans CB. Elevated miR-29c-5p Expression in Nipple Aspirate Fluid Is Associated with Extremely High Mammographic Breast Density. Cancers (Basel) 2022; 14:cancers14153805. [PMID: 35954468 PMCID: PMC9367509 DOI: 10.3390/cancers14153805] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 08/01/2022] [Accepted: 08/03/2022] [Indexed: 11/25/2022] Open
Abstract
Simple Summary High mammographic density is a known risk factor for breast cancer. However, the underlying mechanisms of high mammographic density development and breast cancer are unknown. MicroRNAs are potential biomarkers indicative of carcinogenesis and can be assessed in nipple aspirate fluid. We used nipple aspirate fluid from women with very low and extremely high mammographic density to examine differences in expression of multiple miRNAs between both extremes in the spectrum of mammographic density. We found that hsa-miR-29c-5p was upregulated in an extremely high mammographic density context and potential targets were identified that might provide clues of the relationship between high mammographic density and breast cancer risk. Understanding the relationship between high mammographic density and breast cancer is of great value for early breast cancer diagnosis and treatment. With our research we provide new insight into this relationship and further research could determine the effects of dysregulated hsa-miR-29c-5p on the identified candidate targets. Abstract High mammographic density (MD) is associated with an increased risk of breast cancer, however the underlying mechanisms are largely unknown. This research aimed to identify microRNAs (miRNAs) that play a role in the development of extremely dense breast tissue. In the discovery phase, 754 human mature miRNAs were profiled in 21 extremely high MD- and 20 very low MD-derived nipple aspirate fluid (NAF) samples from healthy women. In the validation phase, candidate miRNAs were assessed in a cohort of 89 extremely high MD and 81 very low MD NAF samples from healthy women. Independent predictors of either extremely high MD or miRNA expression were identified by logistic regression and linear regression analysis, respectively. mRNA targets and pathways were identified through miRTarBase, TargetScan, and PANTHER pathway analysis. Statistical analysis identified four differentially expressed miRNAs during the discovery phase. During the validation, linear regression (p = 0.029; fold change = 2.10) and logistic regression (p = 0.048; odds ratio = 1.38) showed that hsa-miR-29c-5p was upregulated in extremely high MD-derived NAF. Identified candidate mRNA targets of hsa-miR-29c-5p are CFLAR, DNMT3A, and PTEN. Further validation and exploration of targets and downstream pathways of has-miR-29c-5p will provide better insight into the processes involved in the development of high MD and in the associated increased risk of breast cancer.
Collapse
Affiliation(s)
- Tessa A. C. M. Vissers
- Department of Pathology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
| | - Leonie Piek
- Department of Pathology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
| | - Susana I. S. Patuleia
- Department of Pathology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
- Department of Medical Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
| | - Aafke J. Duinmeijer
- Department of Medical Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
| | - Marije F. Bakker
- Department of Epidemiology of the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
| | - Elsken van der Wall
- Department of Medical Oncology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
| | - Paul J. van Diest
- Department of Pathology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
| | - Carla H. van Gils
- Department of Epidemiology of the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
| | - Cathy B. Moelans
- Department of Pathology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands
- Correspondence: ; Tel.: +31-887-556-882
| |
Collapse
|
4
|
Patuleia SIS, Suijkerbuijk KPM, van der Wall E, van Diest PJ, Moelans CB. Nipple Aspirate Fluid at a Glance. Cancers (Basel) 2021; 14:cancers14010159. [PMID: 35008326 PMCID: PMC8750428 DOI: 10.3390/cancers14010159] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 12/20/2021] [Accepted: 12/26/2021] [Indexed: 11/21/2022] Open
Abstract
Simple Summary Nipple aspirate fluid (NAF) is a promising source of markers for detection of breast cancer. NAF can be acquired via the nipple by aspiration using a suction device, which is well tolerated by women. Future possible applications of biomarkers for breast cancer derived from NAF could be (1) as a detection tool to identify the initiation of the cancer development process, (2) as an additional tool next to imaging (mammography and breast magnetic resonance imaging) or (3) as a replacement tool for when imaging is not advisable for women, such as during pregnancy and breastfeeding. With this paper, we present a narrative review and perspectives of NAF research at a glance. Abstract Nipple aspirate fluid (NAF) is an intraductal mammary fluid that, because of its close proximity to and origin from the tissue from which breast cancer originates, is a promising source of biomarkers for early breast cancer detection. NAF can be non-invasively acquired via the nipple by aspiration using a suction device; using oxytocin nasal spray helps increase yield and tolerability. The aspiration procedure is generally experienced as more tolerable than the currently used breast imaging techniques mammography and breast magnetic resonance imaging. Future applications of NAF-derived biomarkers include their use as a tool in the detection of breast carcinogenesis at its earliest stage (before a tumor mass can be seen by imaging), or as a supporting diagnostic tool for imaging, such as when imaging is less reliable (to rule out false positives from imaging) or when imaging is not advisable (such as during pregnancy and breastfeeding). Ongoing clinical studies using NAF samples will likely shed light on NAF’s content and clinical potential. Here, we present a narrative review and perspectives of NAF research at a glance.
Collapse
Affiliation(s)
- Susana I. S. Patuleia
- Department of Pathology, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands; (S.I.S.P.); (P.J.v.D.)
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands; (K.P.M.S.); (E.v.d.W.)
| | - Karijn P. M. Suijkerbuijk
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands; (K.P.M.S.); (E.v.d.W.)
| | - Elsken van der Wall
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands; (K.P.M.S.); (E.v.d.W.)
| | - Paul J. van Diest
- Department of Pathology, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands; (S.I.S.P.); (P.J.v.D.)
| | - Cathy B. Moelans
- Department of Pathology, University Medical Center Utrecht, Utrecht University, 3508 GA Utrecht, The Netherlands; (S.I.S.P.); (P.J.v.D.)
- Correspondence:
| |
Collapse
|